Sumitomo Pharmaceuticals Company Limited

Dainippon Sumitomo Pharma Co., Ltd.

Koken Company, Limited

Keio University

National Cancer Center

Sumitomo Dainippon Pharma Co., Ltd.

Dow Corning Asia Limited

Akihiko Sano

Hiroo Maeda

Masako Kajihara

Keiichi Ono

Yoshiyuki Kai

Takahiro Ochiya

Masaaki Terada

Toshihiko Sugie

Shunji Nagahara

Hideyuki Okano

Hiroshi Itoh

Keiji Fujioka

Yoshiaki Takebayashi

Masaya Nakamura

Yu Aso

Kimi Honma

Akiyoshi Kishino

Shunsuke Tani

Kazushi Suwa

Norimasa Koseki

Takeshi Hirasawa

Shuichi Sugawara

Yosuke Urabe

Akihiko Hisada

Liang Zhang

Miho Maeda

Syunsuke Tani

Shunji 3-348 Sumitomokagaku Nagahara

Masayasu Furuse

Shunichiro Kubota

Takahiro 218 National Cancer Center Ochiya

The present invention is a solid sustained-release formulation comprising an agent for inhibiting semaphorin 3A as an active ingredient, which comprises an agent for inhibiting semaphorin 3A and pharmaceutically acceptable hardly water-soluble solid substance, in which the carrier is silicone.

Preparation for treatment of spinal cord injury

Means for transferring efficiently a desired nucleic acid into a cell is provided. The present invention comprises using a complex comprising a collagen or a collagen derivative, and a desired nucleic acid.

Method of promoting nucleic acid transfer

The present invention relates to a formulation for implantation having a novel constitution, which accomplishes controlled releases of active ingredients. The formulation comprises one of combinations (a), (b) and (c), as well as a carrier comprising a hydrophobic polymer, wherein the particle combination is dispersed into the carrier: (a) particles comprising an active ingredient, particles comprising a carbonate, and particles comprising a substance which is reacted with the carbonate in an aqueous solution to generate carbon dioxide (substance such as an acid); (b) particles comprising an active ingredient and a carbonate, and particles comprising a substance such as an acid; and (c) particles comprising a carbonate, and particles comprising an active ingredient and a substance such as an acid.

Sustained-release drug formulations

Sustained-release drug formulations for implantation

Preparations whereby two or more drugs can be released separately at appropriate speeds depending on the disease or the release behaviors of one or more drugs can be precisely controlled, which consist of an outer layer wherein a water-soluble drug is dispersed in a carrier made of a biologically non-degradable and hydrophobic polymer material, and one or more inner layers wherein a water-soluble drug, differing in kind or concentration from the one contained in the outer layer, is dispersed in a carrier made of a biologically non-degradable and hydrophobic polymer material, and in which the outer and inner layers are concentrically located in diametral direction of rod-like preparations and both or one of the ends in the axial direction are opened so as to directly come into contact with the environment.

Controlled release preparations having multi-layer structure

The invention is directed to the retention of the stability of formulations useful for a gene therapy during the preparation and preservation. In the invention, at least one saccharide and/or at least one non-hydrophobic amino acid and/or at least one organic acid having two or more carboxyl groups except amino acids, or a collagen or a gelatin and at least one amino acid are added to a gene formulation.

Stable gene preparations

The present invention relates to a sustained release preparation of a lipophilic drug, comprising a drug dispersion wherein the lipophilic drug and a water-soluble substance are dispersed, in a solid state at the body temperature of an animal or a human being to which the preparation is to be administered, in a water-impermeable and biocompatible material.

Long time drug-sustained release preparation

The present invention relates to a sustained release formulation used for treatment or prevention of the diseases, which contains a therapeutically effective substance as an active ingredient, collagen as a drug carrier, and glycosaminoglycan as an additive. The formulation allows controlled release of the therapeutically effective substance.

Sustained release formulation

A drug formulation for producing sustained therapeutic efficacy, which releases at least one water-soluble drug over a prolonged period of time at a substantially constant rate wherein said drug formulation comprises

Controlled release drug formulation of open end cylindrical rod form

A polyethylene glycol derivative of the formula ##STR1## wherein R represents a lower alkyl and n represents an optional positive integer which renders the average molecular weight of the polyethylene glycol moiety about 1,000 to 12,000, a peptide modified by said polyethylene glycol derivative and a method for production thereof. The polyethylene glycol derivative (I) is capable of modifying the guanidino groups in peptides. The peptides modified by the polyethylene glycol derivative (I) are extremely stable, are considerably delayed in biological clearance (i.e. the durability is extended) and exhibit their physiological activities effectively over the long period.

Polyethylene glycol derivatives, modified peptides and production thereof

Polyethylene glycol substituted phenyl glyoxals

A process for the manufacture of a polypeptide (I) having the formula: ##STR1## which comprises steps of: (a) coupling, successively and in the order of the sequence of the polypeptide (I), the four protected fragments A, B, C and D or five protected fragments A, B, C, E and F,

Synthesis of a derivative of GRF and intermediate peptides

Growing community of inventors

Toyonaka, Japan

Akihiko Sano